Clinical trials: Dopamine
Cognition Disorder, Attention Deficit Disorder
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI).
- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Trial name
- DAPET-TBI (NCT02225106)
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Schizophrenia
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
- Trial name
- NCT02333487
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical…
- Trial name
- HOSCAR (NCT01278342)
- Testing
- Sandostatin LAR, pegvisomant, cabergoline
- Where
- 20 sites in France, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Parkinsonian Signs in Older Persons
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls.
- Trial name
- RES (NCT06219915)
- Testing
- Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan
Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA)
An Investigation of Early Life Stress and Depression
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).
- Trial name
- NCT01701258
- Testing
- Amisulpride
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Narcolepsy With Cataplexy, Healthy Controls
Xyrem and Brain Dopamine in Narcolepsy
The overall aim of this investigation is to establish whether an action of Xyrem® on the brain dopamine system in patients with narcolepsy, and in a comparison control group, might explain part of the anti-narcoleptic effect of…
- Trial name
- NCT02637076
- Testing
- Xyrem
- Where
- Canada
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
- Trial name
- NCT03544229
- Testing
- TAK-906 Maleate
- Where
- 109 sites in United States, Belgium and 2 more
- Volunteers
- 242 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Alcohol Use Disorder
Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation…
- Trial name
- NCT02949934
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Opiod Use Disorder
The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers
Background: Opioids are medicines that control pain. But they are often misused, which can lead to illness and death. Opioids increase dopamine to the brain, which makes people feel good and often causes them to crave drugs…
- Trial name
- NCT03831971
- Testing
- ANS-6637
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Parkinson Disease
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
- Trial name
- TEAL (NCT04369430)
- Testing
- AKST4290
- Where
- 22 sites in United States, Estonia and 3 more
- Volunteers
- 110 people
- Sponsor
- Alkahest, Inc.
Parkinson's Disease
Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy.
- Trial name
- FOG (NCT03647137)
- Testing
- Detailed motor testing, including FoG, in PD subjects
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- VA Office of Research and Development
Healthy Volunteers
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
The purpose of this study is to determine brain penetration of single oral doses of TAK-041 and its effects on amphetamine-induced dopamine release in the Central Nervous System (CNS).
- Trial name
- NCT02959892
- Testing
- Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
The purpose of the study is to determine if reducing or eliminating a dopamine agonist (DA) causing one of the side effects of daytime sleepiness, swelling of the lower legs or feet, hallucinations or impulsive behaviors while…
- Trial name
- AtoZ (NCT00443872)
- Testing
- orally disintegrating selegiline (Zelapar)
- Where
- 17 sites in United States
- Volunteers
- 77 people
- Sponsor
- Parkinson's Disease and Movement Disorder Center of Boca Raton
Posttraumatic Stress Disorder
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
This study proposes a multi-site, randomized, double-blind, placebo-controlled clinical trial of the dopamine-ß-hydroxylase (DBH) inhibitor, nepicastat, for the treatment of posttraumatic stress disorder (PTSD) in outpatients who…
- Trial name
- Nepicastat (NCT00659230)
- Testing
- Nepicastat
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
Cocaine Dependence
Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse
This project proposes to investigate the role of brain connectivity in the mechanism of treatment response to dopaminergic medications in cocaine dependence.
- Trial name
- NCT02080819
- Testing
- levodopa/carbidopa 400/100 BID
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Healthy
PET Study Examining the Dopaminergic Activity of Armodafinil in Adults
The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the…
- Trial name
- NCT00592943
- Testing
- armodafinil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital